NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00003606,Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00003606,,COMPLETED,"RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether combination chemotherapy with or without epirubicin and cyclophosphamide is more effective in treating patients with extensive stage small cell lung cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without epirubicin and cyclophosphamide in treating patients who have extensive stage small cell lung cancer.",NO,Lung Cancer,DRUG: cisplatin|DRUG: cyclophosphamide|DRUG: epirubicin hydrochloride|DRUG: etoposide|RADIATION: radiation therapy,,,,UNICANCER,,ALL,"ADULT, OLDER_ADULT",PHASE3,216,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT,CDR0000066683|FRE-FNCLCC-95012|EU-98021,1996-03,1999-10-01,2001-06,2004-05-21,,2021-02-21,"Hopital Arnaud de Villeneuve, Montpellier, 34295, France",
